Trademark: 88329711
Word
AMGEN BIOSIMILARS
Status
Dead
Status Code
606
Status Date
Monday, February 13, 2023
Serial Number
88329711
Mark Type
3000
Filing Date
Thursday, March 7, 2019
Published for Opposition
Tuesday, November 12, 2019
Abandoned Date
Monday, February 13, 2023

Trademark Owner History
Amgen Inc. - Owner At Publication

Classifications
5 House mark for a full line of pharmaceuticals and pharmaceutical preparations, namely, pharmaceutical preparations and substances used for the treatment of bone, joint, vertebral column, intestine, colon, skin, lung, eye, breast, ovary, cervix, stomach, bladder, kidney, head, brain, neck, and blood diseases and disorders; pharmaceutical preparations and substances for the treatment of autoimmune, immune system, inflammatory, inflammatory bowel, gastrointestinal, genitourinary, musculoskeletal, dermatological, pulmonary, respiratory, oncological, hepatological, lymphomas, leukemias, ophthalmic, transplant rejection, cardiovascular, endocrine, neurological, sleep, muscular, and psychiatric diseases and disorders;pharmaceutical preparations and substances used for the treatment of arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, juvenile idiopathic arthritis, enthesitis related arthritis, osteoarthritis, peripheral spondyloarthritis, polymyalgia rheumatic, spondyloarthropathies, acute disc prolapse, inflammatory bowel disease, Crohn's disease, ulcerative colitis, Intestinal Behçet's Disease, chronic pouchitis, small bowel lesions, Hermansky-Pudlak syndrome, autoimmune pancreatitis, multiple myeloma, multiple sclerosis, systemic lupus erythematosus, lupus nephritis, chronic inflammatory demyelinating polyneuropathy, autoimmune anemia, autoimmune hemolytic anemia, pure red cell aplasia, idiopathic thrombocytopenic purpura, Evans syndrome, type 1 diabetes mellitus, Sjogren's syndrome, encephalitis, IgG4-related disease, Devic's disease, myositis, psoriasis, psoriasis vulgaris, psoriasis arthropica, plaque psoriasis, palmoplantar psoriasis, hidradenitis suppurativa, bullous skin disorder, pemphigus, pemphigoid, kawasaki disease, interstitial cystitis, sleep apnea, sarcoidosis, retinal vascular disorders, age-related macular degeneration, refractory diabetic macular edema, uveitis, childhood uveitis, uveitic macular edema, choroidal neovascularization, Graves' ophthalmopathy, pyoderma gangrenosum, giant cell arteritis, Netherton syndrome, anaplastic thyroid cancer, breast cancer, ovarian cancer, cervical cancer, gastric cancer, colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma, renal cell carcinoma, head and neck cancer, Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, lymphocyte predominant subtype of Hodgkin's Lymphoma, vasculitis, granulomatosis with polyangiitis, microscopic polyangiitis, graft-versus-host disease, graft-versus-host disease following allogenic hematopoietic stem cell transplantation, graft-versus-host disease following keratoprosthesis, kidney transplant, asthma, chronic fatigue syndrome, major depression, and bipolar depression
The mark consists of the stylized words "AMGEN BIOSIMILARS" positioned to the right of an interweaving double ribbon design.
Color is not claimed as a feature of the mark.
"BIOSIMILARS"

Trademark Events
Feb 13, 2023
Abandonment Notice E-Mailed - No Use Statement Filed
Feb 13, 2023
Abandonment - No Use Statement Filed
Jun 16, 2022
Notice Of Approval Of Extension Request E-Mailed
Jun 15, 2022
Sou Extension 5 Granted
Jun 7, 2022
Sou Extension 5 Filed
Jun 15, 2022
Case Assigned To Intent To Use Paralegal
Jun 7, 2022
Sou Teas Extension Received
Dec 2, 2021
Notice Of Approval Of Extension Request E-Mailed
Nov 30, 2021
Sou Extension 4 Granted
Nov 30, 2021
Sou Extension 4 Filed
Nov 30, 2021
Sou Teas Extension Received
May 6, 2021
Teas Change Of Correspondence Received
May 6, 2021
Teas Withdrawal Of Attorney Received-Firm Retains
May 6, 2021
Attorney/Dom.Rep.Revoked And/Or Appointed
May 6, 2021
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
May 6, 2021
Notice Of Approval Of Extension Request E-Mailed
May 4, 2021
Sou Extension 3 Granted
May 4, 2021
Sou Extension 3 Filed
May 4, 2021
Sou Teas Extension Received
Dec 22, 2020
Notice Of Approval Of Extension Request E-Mailed
Dec 18, 2020
Sou Extension 2 Granted
Dec 18, 2020
Sou Extension 2 Filed
Dec 18, 2020
Sou Teas Extension Received
Jul 1, 2020
Notice Of Approval Of Extension Request E-Mailed
Jun 29, 2020
Sou Extension 1 Granted
Jun 29, 2020
Sou Extension 1 Filed
Jun 29, 2020
Sou Teas Extension Received
Mar 2, 2020
Assigned To Examiner
Jan 7, 2020
Noa E-Mailed - Sou Required From Applicant
Nov 12, 2019
Official Gazette Publication Confirmation E-Mailed
Nov 12, 2019
Published For Opposition
Oct 23, 2019
Notification Of Notice Of Publication E-Mailed
Oct 9, 2019
Approved For Pub - Principal Register
Oct 4, 2019
Teas/Email Correspondence Entered
Oct 4, 2019
Correspondence Received In Law Office
Sep 23, 2019
Assigned To Lie
Sep 12, 2019
Assigned To Lie
Sep 6, 2019
Teas Response To Office Action Received
Mar 30, 2019
Notification Of Non-Final Action E-Mailed
Mar 30, 2019
Non-Final Action E-Mailed
Mar 30, 2019
Non-Final Action Written
Mar 26, 2019
Assigned To Examiner
Mar 26, 2019
Notice Of Design Search Code E-Mailed
Mar 25, 2019
New Application Office Supplied Data Entered
Mar 11, 2019
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24